CEO Ulf Hannelius has been invited to give a talk at the "Precision medicine - From patient to lab and back again" conference organized by the Copenhagen Bioscience Cluster, a Novo Nordisk foundation initiative.
The talk, which is based on an abstract submitted to the conference entitled "Developing data-driven precision therapies for Type 1 diabetes", will focus on how the data collected in Diamyd Medical's clinical trials together with scientific advances in the field have informed the development of the precision medicine diabetes vaccine Diamyd[®] for the treatment of type 1 diabetes. The conference will be held digitally May 2[nd ]to 6[th]
More information about the conference can be found here: https://cph-bioscience.com/en/events/cbc21-2may2021
About Diamyd Medical
Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd[®] is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd[®]. Diamyd Medical also develops the GABA-based investigational drug Remygen[®] as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen[®] trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.
Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: